Journal: Journal of Transplantation

Article Title: Resolution of Mild Ganciclovir-Resistant Cytomegalovirus Disease with Reduced-Dose Cidofovir and CMV-Hyperimmune Globulin

doi: 10.1155/2014/342319

Figure Lengend Snippet: Characteristics of ganciclovir-resistant cytomegalovirus and treatment.

Article Snippet: Each patient was then initiated on combined therapy with intravenous (IV) cidofovir 1-2 mg per kg in 500–1000 mL of normal saline and CMV-IgG (Cytogam, CSL Behring AG, King of Prussia, PA) 100 mg per kg.

Techniques: Biomarker Discovery, Mutagenesis

Journal: Nature Biotechnology

Article Title: The growth and potential of human antiviral monoclonal antibody therapeutics

doi: 10.1038/nbt1363

Figure Lengend Snippet: Antiviral immunoglobulin products on the US market

Article Snippet: Intravenous CMV immunoglobulin , Cytogam , MedImmune , Prophylaxis of CMV associated with transplantation of kidney, lung, liver, pancreas and heart..

Techniques: Infection, Transplantation Assay, Modification

Journal: Life

Article Title: Effectiveness of Prophylactic Human Cytomegalovirus Hyperimmunoglobulin in Preventing Cytomegalovirus Infection following Transplantation: A Systematic Review and Meta-Analysis

doi: 10.3390/life12030361

Figure Lengend Snippet: Rate of CMV infection among SOT patients receiving any prophylactic CMVIG. Abbreviations: CI, confidence interval; CMV, cytomegalovirus; CMVIG, cytomegalovirus-specific hyperimmunoglobulin; SOT, solid organ transplantation.

Article Snippet: Studies employing any CMVIG product were included in the first set of meta-analyses, whereas the second set of meta-analyses specifically addressed the two currently available CMVIG products: (i) Cytotect CP (and its predecessor Cytotect) and the other brand names under which it is marketed (e.g., Megalotect; Biotest AG, Dreieich, Germany) , and (ii) Cytogam (Saol Therapeutics, Roswell, GA, USA; formerly manufactured by CSL Behring AG, Bern, Switzerland).

Techniques: Infection, Transplantation Assay

Journal: Life

Article Title: Effectiveness of Prophylactic Human Cytomegalovirus Hyperimmunoglobulin in Preventing Cytomegalovirus Infection following Transplantation: A Systematic Review and Meta-Analysis

doi: 10.3390/life12030361

Figure Lengend Snippet: Meta-analysis of CMV infection rates in solid organ transplantation for CMVIG vs. control groups.

Article Snippet: Studies employing any CMVIG product were included in the first set of meta-analyses, whereas the second set of meta-analyses specifically addressed the two currently available CMVIG products: (i) Cytotect CP (and its predecessor Cytotect) and the other brand names under which it is marketed (e.g., Megalotect; Biotest AG, Dreieich, Germany) , and (ii) Cytogam (Saol Therapeutics, Roswell, GA, USA; formerly manufactured by CSL Behring AG, Bern, Switzerland).

Techniques: Infection, Transplantation Assay, Control, Biomarker Discovery

Journal: Life

Article Title: Effectiveness of Prophylactic Human Cytomegalovirus Hyperimmunoglobulin in Preventing Cytomegalovirus Infection following Transplantation: A Systematic Review and Meta-Analysis

doi: 10.3390/life12030361

Figure Lengend Snippet: Rate of CMV infection among SOT patients receiving Cytotect or Cytogam. Abbreviations: CI, confidence interval; CMV, cytomegalovirus; CMVIG, cytomegalovirus-specific hyperimmunoglobulin; SOT, solid organ transplantation.

Article Snippet: Studies employing any CMVIG product were included in the first set of meta-analyses, whereas the second set of meta-analyses specifically addressed the two currently available CMVIG products: (i) Cytotect CP (and its predecessor Cytotect) and the other brand names under which it is marketed (e.g., Megalotect; Biotest AG, Dreieich, Germany) , and (ii) Cytogam (Saol Therapeutics, Roswell, GA, USA; formerly manufactured by CSL Behring AG, Bern, Switzerland).

Techniques: Infection, Transplantation Assay

Journal: Life

Article Title: Effectiveness of Prophylactic Human Cytomegalovirus Hyperimmunoglobulin in Preventing Cytomegalovirus Infection following Transplantation: A Systematic Review and Meta-Analysis

doi: 10.3390/life12030361

Figure Lengend Snippet: Rate of CMV infection among SOT patients receiving any prophylactic CMVIG, in studies detecting CMV infection via pp65 antigenemia and/or CMV DNAemia. Abbreviations: CI, confidence interval; CMV, cytomegalovirus; CMVIG, cytomegalovirus-specific hyperimmunoglobulin; SOT, solid organ transplantation.

Article Snippet: Studies employing any CMVIG product were included in the first set of meta-analyses, whereas the second set of meta-analyses specifically addressed the two currently available CMVIG products: (i) Cytotect CP (and its predecessor Cytotect) and the other brand names under which it is marketed (e.g., Megalotect; Biotest AG, Dreieich, Germany) , and (ii) Cytogam (Saol Therapeutics, Roswell, GA, USA; formerly manufactured by CSL Behring AG, Bern, Switzerland).

Techniques: Infection, Transplantation Assay

Journal: Therapeutic Antibodies

Article Title: Therapeutic Antibodies: Current State and Future Trends – Is a Paradigm Change Coming Soon?

doi: 10.1007/978-1-59745-554-1_1

Figure Lengend Snippet: Antibodies approved by the US FDA for clinical use. In addition to all approved monoclonal antibodies for prevention and treatment (indicated in bold) as of March 2008 the list (not exhaustive) also includes several polyclonal antibody preparations and a monoclonal antibody for imaging. Note that the same antibody can be approved for different indications at different times. The antibodies are arranged alphabetically according to their brand names

Article Snippet: CytoGam ® (CMV immune globulin IV) , MedImmune, Inc. , Prevention of cytomegalovirus (CMV) disease associated with kidney, lung, liver, pancreas, and heart transplants; Prevention of CMV in transplant patients , Apr. 1990 Dec. 1998.

Techniques: Bioprocessing, Imaging, Transformation Assay, Labeling, Injection, Virus, Isolation, Infection, Activity Assay